Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 11 | 2026 | 1334 | 1.870 |
Why?
|
| Poverty Areas | 6 | 2026 | 52 | 1.620 |
Why?
|
| Tissue Engineering | 5 | 2016 | 74 | 1.130 |
Why?
|
| Colorectal Neoplasms | 3 | 2026 | 302 | 1.050 |
Why?
|
| Poverty | 5 | 2026 | 233 | 0.840 |
Why?
|
| Health Status Disparities | 2 | 2025 | 221 | 0.790 |
Why?
|
| Oxygen | 2 | 2016 | 338 | 0.770 |
Why?
|
| Anniversaries and Special Events | 1 | 2022 | 3 | 0.740 |
Why?
|
| Biophysical Phenomena | 1 | 2018 | 15 | 0.570 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 46 | 0.520 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 158 | 0.520 |
Why?
|
| Patient Participation | 1 | 2017 | 72 | 0.510 |
Why?
|
| Cell Culture Techniques | 3 | 2015 | 99 | 0.480 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 40 | 0.470 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 67 | 0.440 |
Why?
|
| Microtechnology | 2 | 2013 | 4 | 0.430 |
Why?
|
| Biomedical Research | 1 | 2017 | 267 | 0.430 |
Why?
|
| Natural Science Disciplines | 1 | 2013 | 2 | 0.410 |
Why?
|
| Rural Population | 2 | 2025 | 596 | 0.300 |
Why?
|
| Humans | 19 | 2026 | 53230 | 0.260 |
Why?
|
| Insurance Coverage | 2 | 2024 | 124 | 0.240 |
Why?
|
| Registries | 2 | 2025 | 652 | 0.220 |
Why?
|
| Cancer Care Facilities | 1 | 2024 | 20 | 0.220 |
Why?
|
| Urban Population | 1 | 2025 | 162 | 0.210 |
Why?
|
| Proportional Hazards Models | 1 | 2025 | 445 | 0.210 |
Why?
|
| Tumor Microenvironment | 2 | 2018 | 274 | 0.210 |
Why?
|
| Survival Analysis | 1 | 2025 | 659 | 0.200 |
Why?
|
| Endothelium, Vascular | 2 | 2015 | 262 | 0.190 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2022 | 31 | 0.190 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2021 | 10 | 0.170 |
Why?
|
| Ecosystem | 1 | 2022 | 99 | 0.170 |
Why?
|
| Aged | 5 | 2026 | 10429 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 312 | 0.170 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 43 | 0.170 |
Why?
|
| Models, Biological | 2 | 2013 | 737 | 0.160 |
Why?
|
| Middle Aged | 5 | 2026 | 13419 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 330 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 219 | 0.140 |
Why?
|
| United States | 3 | 2026 | 5409 | 0.140 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2015 | 102 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 645 | 0.130 |
Why?
|
| Kinetics | 1 | 2018 | 607 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 2 | 2013 | 86 | 0.120 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 7 | 0.110 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 11 | 0.110 |
Why?
|
| Alginates | 1 | 2015 | 12 | 0.110 |
Why?
|
| Hydrogels | 1 | 2015 | 26 | 0.110 |
Why?
|
| Interleukin-8 | 1 | 2015 | 85 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 82 | 0.110 |
Why?
|
| Arkansas | 3 | 2026 | 2068 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 441 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 281 | 0.110 |
Why?
|
| Female | 5 | 2026 | 28782 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 412 | 0.100 |
Why?
|
| Microvessels | 1 | 2013 | 36 | 0.100 |
Why?
|
| Chemical Phenomena | 1 | 2013 | 13 | 0.100 |
Why?
|
| Microfluidics | 1 | 2013 | 7 | 0.100 |
Why?
|
| Male | 4 | 2026 | 27435 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 148 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2024 | 742 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 868 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2023 | 384 | 0.080 |
Why?
|
| Inflammation | 1 | 2015 | 652 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1112 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2015 | 1748 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1232 | 0.060 |
Why?
|
| Geographic Information Systems | 1 | 2024 | 15 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2024 | 42 | 0.050 |
Why?
|
| Adult | 3 | 2024 | 14534 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2024 | 146 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 204 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 229 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 623 | 0.040 |
Why?
|
| Animals | 2 | 2013 | 13526 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 263 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 190 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2026 | 477 | 0.040 |
Why?
|
| Enzyme Stability | 1 | 2021 | 21 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 317 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1723 | 0.040 |
Why?
|
| Risk Factors | 1 | 2026 | 4017 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 1470 | 0.030 |
Why?
|
| Infant | 1 | 2024 | 3805 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2024 | 4162 | 0.030 |
Why?
|
| Young Adult | 1 | 2024 | 4511 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2026 | 6819 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 68 | 0.030 |
Why?
|
| Biological Transport | 1 | 2013 | 150 | 0.030 |
Why?
|
| Optical Imaging | 1 | 2013 | 27 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 146 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2013 | 83 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 141 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 6907 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 189 | 0.020 |
Why?
|
| Child | 1 | 2024 | 7379 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2013 | 289 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 1569 | 0.020 |
Why?
|